Abstract
Background and Hypotheses We sought to evaluate the ability of automated speech and language features to track fluctuations in the major psychosis symptoms domains: Thought Disorder, Negative Symptoms, and Positive Symptoms.
Study Design Sixty-six participants with psychotic disorders were longitudinally assessed soon after inpatient admission, at discharge, and at 3- and 6-months. Psychosis symptoms were measured with semi-structured interviews and standardized scales. Recordings were collected from paragraph reading, fluency, picture description, and open-ended tasks. Longitudinal relationships between psychosis symptoms and 357 automated speech and language features were analyzed using a single component score and as individual features, using linear mixed models.
Study Results All three psychosis symptom domains demonstrated significant longitudinal relationships with the single component score. Thought Disorder was particularly related to features describing more subordinated constructions, less efficient identification of picture elements, and decreased semantic distance between sentences. Negative Symptoms was related to features describing decreased speech complexity. Positive Symptoms appeared heterogeneous, with Suspiciousness relating to greater use of nouns, and Hallucinations related to decreased semantic distances. These relationships were largely robust to interactions with gender and race. However, interactions with timepoint revealed variable relationships during different phases of illness (acute vs. stable).
Conclusions Automated speech and language features show promise as scalable, objective markers of psychosis severity. The three symptom domains appear to be distinguishable with different features. Detailed attention to clinical setting and patient population is needed to optimize clinical translation; there are substantial implications for facilitating differential diagnosis, improving psychosis outcomes and enhancing therapeutic discovery.
Competing Interest Statement
SXT owns equity and serves on the board and as a consultant for North Shore Therapeutics, received research funding and serves as a consultant for Winterlight Labs, is on the advisory board and owns equity for Psyrin, and serves as a consultant for LB Pharmaceuticals and Catholic Charities Neighborhood Services. MJS and BS are employees of Cambridge Cognition. MLB owns equity and serves as a consultant for North Shore Therapeutics. AKM serves on the Data Safety Monitoring Board for IQVIA. JMK has received consulting fees or honoria for lectures from Alkermes, Boerhinger Ingelheim, Cerevel, Click Therapeutics, Intracellular Therapies, H. Lundbeck, HLS, Janssen, Johnson and Johnson, Merck, Minerva, Neurocrine, Newron, Otsuka, Roche, Saladax and Teva. He is a shareholder in Cerevel, HealthRyhthms, LB Pharma, North Shore Therapeutics and The Vanguard Research Group. He has received grant support from H. Lundbeck, Otsuka, Merck, Sunovion and Valera.
Funding Statement
Funding for this study was received from Winterlight Labs, NIH K23 MH130750 (SXT), and the Brain and Behavior Research Foundation Young Investigator Grant (SXT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research procedures were approved by the institutional review board at Northwell Health, and all participants provided written consent after decisional capacity was confirmed. The study was registered on ClinicalTrials.gov (NCT05601050).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Deidentified, processed data produced in the present study are available upon reasonable request to the authors.
